Reference
- Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3–8.
- Zur HH. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384:260–265.
- Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203.
- Jaisamrarn U, Castellsagué X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013;8:e79260.
- Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1:2–10.
- Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
- Giorgi-Rossi P, Franceschi S, Ronco G. HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer. 2012;130:1387–1394.
- Evans W, Filippova M, Swensen R, et al. Modern molecular and clinical approaches to eradicate HPVmediated cervical cancer. In: book: human papillomavirus and related diseases from bench to bedside a diagnostic and preventive perspective. InTech Open Science. London, UK: IntechOpen; 2013:287-325.
- Capra G, Giovannelli L, Matranga D, et al. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Hum Vaccin Immunother. 2017;13:1839–1843.
- Kane MA, Serrano B, de Sanjose S, et al. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30(Suppl 5):F192–200. .
- Chan PK, Zhang C, Park JS, et al. Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. Int J Cancer. 2013;132:2528–2536.
- Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;370:2161–2170.
- Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–1987.
- Huang HS, Pyeon D, Pearce SM, et al. Novel antivirals inhibit early steps in HPV infection. Antiviral Res. 2012;93:280–287.
- Howett MK, Kuhl JP. Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des. 2005;11:3731–3746.
- Fernández-Romero JA, Thorn M, Turville SG, et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis. 2007;34:9–14.
- Kilmarx PH, Blanchard K, Chaikummao S, et al. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis. 2008;35:226–232.
- McLean CA, van de Wijgert JH, Jones HE, et al. HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand. AIDS. 2010;24:717–722.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med. 2009;151:264–269.
- Handbook for conducting a literature-based health assessment using OHAT approach for systematic review and evidence integration. In: book: OHAT Handbook. 2019 Mar 4:1-96. United States government: Office of Health Assessment and Translation (OHAT) - Division of the National Toxicology Program.
- Buck CB, Thompson CD, Roberts JN, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2:e69.
- Buck CB, Pastrana DV, Lowy DR, et al. Efficient intracellular assembly of papillomaviral vectors. J Virol. 2004;78:751–757.
- Buck CB, Thompson CD, Pang YY, et al. Maturation of papillomavirus capsids. J Virol. 2005;79:2839–2846.
- Pérez-Andino J, Buck CB, Ribbeck K. Adsorption of human papillomavirus 16 to live human sperm. PLoS One. 2009;4:e5847.
- Cruz L, Meyers C. Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PLoS One. 2013;8:e68379.
- Novetsky PA, Keller MJ, Gradissimo A, et al. In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel. Gynecol Oncol. 2016;143:313–318.
- Kizima L, Rodríguez A, Kenney J, et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS One. 2014;9:e94547.
- Rodríguez A, Kleinbeck K, Mizenina O, et al. In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. Antiviral Res. 2014;108:88–93.
- Wang JW, Jagu S, Kwak K, et al. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology. 2014;449:304–316.
- Levendosky K, Mizenina O, Martinelli E, et al. Griffithsin and carrageenan combination to target herpes simplex virus 2 and human papillomavirus. Antimicrob Agents Chemother. 2015;59:7290–7298.
- Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13:857–861.
- Zhang YQ, Tsai YC, Monie A, et al. Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine. 2010;28:5212–5219.
- Roberts JN, Kines RC, Katki HA, et al. Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst. 2011;103:737–743.
- Magnan S, Tota JE, El-Zein M, et al. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. Clin Microbiol Infect. 2019;25:210–216.
- Perino A, Consiglio P, Maranto M, et al. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results. Eur Rev Med Pharmacol Sci. 2019;23:6744–6752.
- Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007;177:469–479.
- Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018;151:229–234.
- Kwak K, Jiang R, Wang JW, et al. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. PLoS One. 2014;9:e97232.